5 ESSENTIAL ELEMENTS FOR ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will get treatment right until illness progression or the contributors are not able to tolerate the study drugs.88 These preclinical studies offer paradigms for long run clinical trials in AML, and using nov